Recon: Merck signs royalty-free deal with Medicines Patent Pool for molnupiravir; Cortexyme's Alzheimer's candidate misses primary endpoint
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy